Resources

A patient with acute viral influenza develops secondary bacterial pneumonia caused by Streptococcus pneumoniae. Viral cytopathic damage to the ciliated tracheal epithelium is modeled as reducing mucociliary bacterial clearance from a baseline of 9.0×105 cells/h9.0 \times 10^5\text{ cells/h} to 1.5×105 cells/h1.5 \times 10^5\text{ cells/h}. Concurrently, the bacterial population in the lower respiratory tract expands exponentially according to N(t)=N0ektN(t) = N_0 e^{kt}, where N0=4.0×103 cellsN_0 = 4.0 \times 10^3\text{ cells} and the net growth rate constant is k=0.693 h−1k = 0.693\text{ h}^{-1} (doubling time td=1.0 ht_d = 1.0\text{ h}). (a) Calculate the bacterial population NN at t=6.0 ht = 6.0\text{ h} in the absence of treatment. (b) Explain why a therapeutic regimen consisting exclusively of oseltamivir (a neuraminidase inhibitor) initiated at t=6.0 ht = 6.0\text{ h} fails to arrest this secondary pulmonary consolidation, and specify the dual-class pharmacotherapy required to address both pathologies.

Answer and steps

Final answer

(a) N(6.0)=(4.0×103)e(0.693)(6.0)=(4.0×103)(26)=(4.0×103)(64)=2.56×105 bacterial cellsN(6.0) = (4.0 \times 10^3) e^{(0.693)(6.0)} = (4.0 \times 10^3)(2^6) = (4.0 \times 10^3)(64) = 2.56 \times 10^5\text{ bacterial cells}. (b) Oseltamivir competitively inhibits viral neuraminidase to prevent the release of newly formed virions from host cells, but has zero activity against prokaryotic physiology or bacterial division. Halting pulmonary consolidation requires dual pharmacotherapy: an antiviral (e.g., oseltamivir) to inhibit primary viral propagation and a bactericidal antibiotic (e.g., amoxicillin or ceftriaxone) targeting bacterial peptidoglycan synthesis.

Steps

Part (a): Calculating the Bacterial Population at t=6.0 ht = 6.0\text{ h}

  1. Identify the Given Parameters for Exponential Growth:

    • Initial bacterial population: N0=4.0×103 cellsN_0 = 4.0 \times 10^3\text{ cells}
    • Net growth rate constant: k=0.693 h−1k = 0.693\text{ h}^{-1}
    • Doubling time: td=ln⁡(2)k=0.6930.693 h−1=1.0 ht_d = \frac{\ln(2)}{k} = \frac{0.693}{0.693\text{ h}^{-1}} = 1.0\text{ h}
    • Elapsed time: t=6.0 ht = 6.0\text{ h}
  2. Calculate the Population Using Doubling Intervals: Since the doubling time is exactly 1.0 h1.0\text{ h}, the number of generations (doublings) in t=6.0 ht = 6.0\text{ h} is: n=ttd=6.0 h1.0 h=6n = \frac{t}{t_d} = \frac{6.0\text{ h}}{1.0\text{ h}} = 6
  3. Evaluate the Exponential Function: N(6.0)=N0ekt=N0⋅2nN(6.0) = N_0 e^{kt} = N_0 \cdot 2^n N(6.0)=(4.0×103)⋅26N(6.0) = (4.0 \times 10^3) \cdot 2^6 N(6.0)=(4.0×103)⋅64=2.56×105 bacterial cellsN(6.0) = (4.0 \times 10^3) \cdot 64 = 2.56 \times 10^5\text{ bacterial cells}

    Common Pitfall: Confusing the continuous rate constant kk with the doubling base. Note that e(0.693)(6.0)=eln⁡(2)⋅6=(eln⁡(2))6=26=64e^{(0.693)(6.0)} = e^{\ln(2) \cdot 6} = (e^{\ln(2)})^6 = 2^6 = 64.


Part (b): Mechanism Failure and Required Dual Pharmacotherapy

  1. Why Oseltamivir Monotherapy Fails:

    • Target Specificity: Oseltamivir is a transition-state analogue that selectively binds to and inhibits the influenza virus neuraminidase (sialidase) enzyme. Neuraminidase is required exclusively by the influenza virus to cleave terminal sialic acid residues on host respiratory glycoproteins, allowing newly assembled virions to bud and disseminate to adjacent cells.
    • Lack of Prokaryotic Activity: Streptococcus pneumoniae is a prokaryotic bacterium. Its proliferation, structural integrity, and virulence do not rely on viral neuraminidase-mediated budding; bacteria divide via binary fission and maintain structural stability through a cross-linked peptidoglycan cell wall. Consequently, oseltamivir exerts no antibacterial or bactericidal activity against S. pneumoniae, allowing unabated bacterial replication and progressive alveolar exudation (consolidation).
  2. Required Dual-Class Pharmacotherapy: To resolve the coinfection, treatment must simultaneously target the primary viral pathogen and the secondary bacterial invader:

    • Antiviral Agent (Neuraminidase Inhibitor): Oseltamivir (or zanamivir) to halt the budding and systemic spread of the influenza virus, thereby limiting further cytopathic destruction of the respiratory epithelium.
    • Antibacterial Agent (Cell Wall Synthesis Inhibitor): A bactericidal antibiotic, such as a β\beta-lactam (e.g., amoxicillin or ceftriaxone), which inhibits bacterial penicillin-binding proteins (transpeptidases), blocking peptidoglycan cell wall synthesis and causing bacterial cell lysis.

Typical errors

OverviewACEpath Teacher's Diagnosis

01 The student misidentifies oseltamivir as an antibiotic capable of treating Streptococcus pneumoniae, concluding that single-agent therapy is sufficient instead of prescribing dual therapy.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    N(6.0)=4.0×103×26=4.0×103×64=2.56×105 cellsN(6.0) = 4.0 \times 10^3 \times 2^6 = 4.0 \times 10^3 \times 64 = 2.56 \times 10^5\text{ cells}

  2. Step 2

    Oseltamivir fails at t=6.0 ht = 6.0\text{ h} solely because the bacterial count 2.56×105 cells2.56 \times 10^5\text{ cells} is too high for a standard dose, so a higher single dose of oseltamivir is sufficient without needing two drug classes.

    Correct

    Oseltamivir selectively inhibits viral neuraminidase to prevent virion release from host cells and has no biochemical target or activity in prokaryotic bacteria like Streptococcus pneumoniae. Halting both pathologies requires dual-class pharmacotherapy: a neuraminidase inhibitor antiviral (e.g., oseltamivir) to curb viral replication and a bactericidal antibiotic (e.g., amoxicillin or ceftriaxone targeting peptidoglycan synthesis) to eradicate the bacterial pneumonia.

    Increasing the dosage of oseltamivir cannot halt bacterial growth because oseltamivir binds only to viral neuraminidase, an enzyme absent in bacteria. You need an antibacterial agent targeting prokaryotic structures alongside the antiviral.

WHAT YOU DID WELL
Compliments from Your Teacher

You correctly applied the doubling time concept to compute the exponential expansion of Streptococcus pneumoniae over 6.0 h6.0\text{ h}.

You accurately computed 26=642^6 = 64 and arrived at the exact bacterial population of 2.56×105 cells2.56 \times 10^5\text{ cells}.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Pharmacological Target Specificity Misconception

no

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You treated an antiviral agent as an antimicrobial with general broad-spectrum coverage whose failure was due to pharmacodynamic saturation (dose size) rather than structural and biological target specificity (prokaryotic versus viral targets).

REASONING PATH
Your ACEpath teacher’s suggested approach
Target Specificity of Antimicrobials
  • Antivirals target viral proteins (e.g., viral polymerases, neuraminidase, proteases), while antibiotics target prokaryotic structures (e.g., peptidoglycan synthesis, bacterial 70S70\text{S} ribosomes).

  • Never prescribe an antiviral to eradicate a bacterium or assume higher dosing compensates for an absent biological drug target.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. State the specific molecular target of oseltamivir: it competitively inhibits influenza viral neuraminidase (sialidase), preventing virion release from host cells.

  2. Explain why oseltamivir does not affect bacteria: Streptococcus pneumoniae is a prokaryote that divides via binary fission and possesses a peptidoglycan cell wall; it does not utilize influenza neuraminidase for replication or survival.

  3. Specify the required dual pharmacotherapy: an antiviral (oseltamivir) to control viral propagation plus a bactericidal antibiotic (such as amoxicillin or ceftriaxone) to disrupt bacterial cell wall cross-linking.

Final answer

(a) N(6.0)=2.56×105 bacterial cellsN(6.0) = 2.56 \times 10^5\text{ bacterial cells}. (b) Oseltamivir selectively targets influenza neuraminidase, which has no role in prokaryotic bacterial physiology; thus, no dosage can treat S. pneumoniae. Effective treatment requires dual pharmacotherapy: an antiviral (oseltamivir) and a bactericidal cell wall inhibitor antibiotic (e.g., amoxicillin or ceftriaxone).

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the distinct structural targets of major antimicrobial classes: antivirals versus antibacterials.

  • Practice explaining secondary coinfections by breaking down the specific pathogen, its cellular biology, and the corresponding therapeutic class required.

OverviewACEpath Teacher's Diagnosis

02 The student confuses the doubling factor 2⁶ with multiplying the initial population by 6, severely underestimating the exponential bacterial growth.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    N(6.0)=4.0×103×6=2.4×104 cellsN(6.0) = 4.0 \times 10^3 \times 6 = 2.4 \times 10^4\text{ cells}

    Correct

    N(6.0)=N0⋅26=(4.0×103)⋅64=2.56×105 cellsN(6.0) = N_0 \cdot 2^6 = (4.0 \times 10^3) \cdot 64 = 2.56 \times 10^5\text{ cells}

    You multiplied the initial population by the elapsed time of 6 hours6\text{ hours} rather than raising the base-2 doubling factor to the 6th power (26=642^6 = 64).

  2. Step 2

    Oseltamivir acts only on influenza virus neuraminidase and lacks antibacterial activity against Streptococcus pneumoniae.

  3. Step 3

    Management requires both an antiviral (oseltamivir) and an antibacterial antibiotic (such as amoxicillin).

WHAT YOU DID WELL
Compliments from Your Teacher

You correctly identified that oseltamivir inhibits viral neuraminidase without exerting antibacterial effects against Streptococcus pneumoniae.

You accurately identified the clinical requirement for dual pharmacotherapy combining an antiviral and a bactericidal antibiotic.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Linear Multiplication Instead of Exponential Growth

no

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You treated the 6 elapsed doubling hours as a linear multiplier of 6 rather than the exponent nn in the exponential doubling factor 2n2^n.

REASONING PATH
Your ACEpath teacher’s suggested approach
Exponential Doubling vs. Linear Multiplication
  • For a population doubling every generation tdt_d, the population size after n=ttdn = \frac{t}{t_d} generations is N(t)=N0⋅2nN(t) = N_0 \cdot 2^n, never N0⋅nN_0 \cdot n.

  • First determine the number of generations n=6.0 h1.0 h=6n = \frac{6.0\text{ h}}{1.0\text{ h}} = 6, compute 26=642^6 = 64, and then multiply by N0N_0.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Determine the number of elapsed doubling periods: n=ttd=6.0 h1.0 h=6n = \frac{t}{t_d} = \frac{6.0\text{ h}}{1.0\text{ h}} = 6.

  2. Set up the exponential doubling model: N(6.0)=N0⋅2n=(4.0×103)⋅26N(6.0) = N_0 \cdot 2^n = (4.0 \times 10^3) \cdot 2^6.

  3. Evaluate the doubling factor: 26=642^6 = 64.

  4. Compute the final bacterial count: N(6.0)=(4.0×103)⋅64=2.56×105 cellsN(6.0) = (4.0 \times 10^3) \cdot 64 = 2.56 \times 10^5\text{ cells}.

Final answer

2.56×105 bacterial cells2.56 \times 10^5\text{ bacterial cells}

NEXT STEPS
Final Takeaways from Your Teacher
  • Practice computing exponential population growth using the base-2 formula N(t)=N0⋅2t/tdN(t) = N_0 \cdot 2^{t/t_d} to build fluency with generation exponents.

  • Contrast the physiological mechanisms of viral budding and bacterial binary fission to reinforce why specific drug classes target only one pathogen domain.

OverviewACEpath Teacher's Diagnosis

03 The student subtracts the clearance rate directly from the total population rather than recognizing clearance is a continuous rate, leading to an incorrect net cell count calculation.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    Ngrowth=4.0×103×26=2.56×105 cellsN_{\text{growth}} = 4.0 \times 10^3 \times 2^6 = 2.56 \times 10^5\text{ cells}

  2. Step 2

    N(6.0)=2.56×105−1.5×105=1.06×105 cellsN(6.0) = 2.56 \times 10^5 - 1.5 \times 10^5 = 1.06 \times 10^5\text{ cells}

    Correct

    N(6.0)=2.56×105 bacterial cellsN(6.0) = 2.56 \times 10^5\text{ bacterial cells}

    You subtracted the reduced clearance rate (1.5×105 cells/h1.5 \times 10^5\text{ cells/h}) directly from the population count (2.56×105 cells2.56 \times 10^5\text{ cells}). Because the problem specifies that the population expands according to N(t)=N0ektN(t) = N_0 e^{kt} with net rate constant kk, clearance effects are already incorporated into kk, and subtracting a rate (cells/h) from an absolute count (cells) violates dimensional consistency.

  3. Step 3

    Oseltamivir specifically inhibits influenza neuraminidase and cannot kill bacteria like Streptococcus pneumoniae. Dual pharmacotherapy requires an antiviral to stop viral spread and an antibacterial agent to eradicate the bacteria.

WHAT YOU DID WELL
Compliments from Your Teacher

You correctly evaluated the exponential growth of the bacterial population using the doubling interval formula.

You accurately identified that oseltamivir specifically targets influenza neuraminidase and is ineffective against bacterial pathogens.

You correctly identified that dual pharmacotherapy requires both an antiviral agent and an antibacterial antibiotic.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Dimensional Inconsistency and Distractor Rate Subtraction

You subtracted the hourly clearance rate directly from the total cell population at the final time point.

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You treated an hourly clearance rate (1.5×105 cells/h1.5 \times 10^5\text{ cells/h}) as a flat quantity of cells to deduct from the standing population, overlooking that the net growth rate constant kk in N(t)=N0ektN(t) = N_0 e^{kt} already accounts for net expansion and that units of cells/h\text{cells/h} cannot be subtracted directly from cells\text{cells}.

REASONING PATH
Your ACEpath teacher’s suggested approach
Verify Unit Compatibility
  • Quantities added or subtracted must share identical physical units. An absolute population has units of [cells][\text{cells}], whereas a clearance rate has units of [cells/time][\text{cells}/\text{time}].

  • Always check units before combining numerical values: never subtract a rate (cells/h)(\text{cells/h}) directly from a state quantity (cells)(\text{cells}) without integrating over time.

Identify Net Growth Parameters
  • When a population model specifies that the total population follows N(t)=N0ektN(t) = N_0 e^{kt} with a net rate constant kk, the net rate already accounts for concurrent birth and removal processes.

  • Use the explicit growth function N(t)=N0ektN(t) = N_0 e^{kt} directly to find the population size at time tt unless instructed to set up an differential balance equation.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Recognize that the net population is fully modeled by N(t)=N0ektN(t) = N_0 e^{kt}, where kk is the net growth rate constant.

  2. Evaluate the function at t=6.0 ht = 6.0\text{ h}: N(6.0)=(4.0×103)⋅26=2.56×105 cellsN(6.0) = (4.0 \times 10^3) \cdot 2^6 = 2.56 \times 10^5\text{ cells}.

  3. Do not subtract the clearance rate 1.5×105 cells/h1.5 \times 10^5\text{ cells/h}, as it represents a rate and is already integrated into the net dynamics.

Final answer

N(6.0)=2.56×105 bacterial cellsN(6.0) = 2.56 \times 10^5\text{ bacterial cells}

NEXT STEPS
Final Takeaways from Your Teacher
  • Always verify dimensional consistency by writing units alongside numbers before performing arithmetic.

  • Identify whether a given growth constant kk represents gross replication or net growth before modifying an exponential model.

Lock it in

Similar question

01

A patient with respiratory syncytial virus (RSV) bronchiolitis develops secondary otitis media caused by non-typeable Haemophilus influenzae. Why would ribavirin monotherapy fail to resolve the middle ear effusion, and what class of antimicrobial must be added?

Answer

Ribavirin is a broad-spectrum viral nucleoside analogue that interferes with viral RNA synthesis and has no activity against bacterial replication. Resolving the secondary bacterial infection requires adding an antibacterial agent, such as an aminopenicillin (e.g., amoxicillin-clavulanate), which inhibits bacterial cell wall synthesis.

02

During an epidemic of Influenza A, an immunocompromised patient develops severe pulmonary infiltration with cavitary lesions yielding Staphylococcus aureus that produces β\beta-lactamase. Design a targeted dual-drug therapeutic regimen and identify the primary molecular target of each selected drug.

Answer

Regimen: Oseltamivir plus a β\beta-lactamase-resistant antibiotic or glycopeptide (e.g., ampicillin-sulbactam, ceftaroline, or vancomycin). Targets: (1) Oseltamivir targets viral neuraminidase to halt virion budding from host epithelial cells. (2) Vancomycin targets bacterial D-Ala-D-Ala cell wall precursors (or ampicillin-sulbactam targets bacterial penicillin-binding proteins while neutralizing β\beta-lactamase), causing bacterial cell lysis.

03

A culture of Klebsiella pneumoniae initially at N0=1.0×104 cellsN_0 = 1.0 \times 10^4\text{ cells} grows exponentially with doubling time td=0.5 ht_d = 0.5\text{ h}. At t=2.0 ht = 2.0\text{ h}, the culture is treated with either (1) a high concentration of rimantadine (an M2 ion channel blocker) or (2) ciprofloxacin (a fluoroquinolone). Calculate the population at t=2.0 ht = 2.0\text{ h} and contrast the biological outcomes of treatment (1) versus treatment (2).

Answer

Population at t=2.0 ht = 2.0\text{ h}: Number of doublings n=2.00.5=4n = \frac{2.0}{0.5} = 4, so N(2.0)=(1.0×104)×24=1.6×105 cellsN(2.0) = (1.0 \times 10^4) \times 2^4 = 1.6 \times 10^5\text{ cells}. Outcome (1): Rimantadine blocks the influenza A viral M2 proton channel; since bacteria lack M2 channels, the bacterial population continues unabated exponential expansion. Outcome (2): Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, arresting DNA replication and causing bactericidal lethality.

Loading workspace…